Extracellular GABA in globus pallidus increases during the induction of oral tremor by haloperidol but not by muscarinic receptor stimulation

Behavioural Brain Research

Volumn 234, Issue 1, 2012, Pages 129-135

  Collins Praino, Lyndsey E ^a,b   Podurgiel, Samantha J ^a   Kovner, Rotem ^a   Randall, Patrick A ^a   Salamone, John D ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Basal ganglia; Dopamine; Microdialysis; Parkinsonism; Pilocarpine; Tremulous jaw movements

Indexed keywords

4 AMINOBUTYRIC ACID; HALOPERIDOL; PILOCARPINE;

4 AMINOBUTYRIC ACID BRAIN LEVEL; 4 AMINOBUTYRIC ACID RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; EXTRACELLULAR SPACE; GLOBUS PALLIDUS; JAW MOVEMENT; MALE; NONHUMAN; PATHOGENESIS; PERIORAL TREMOR; PRIORITY JOURNAL; RAT;

ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; GLOBUS PALLIDUS; HALOPERIDOL; JAW; MALE; MOVEMENT; MUSCARINIC AGONISTS; PILOCARPINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MUSCARINIC; TREMOR;

EID: 84863535868     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.06.011     Document Type: Article

References (76)

1. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression, and mortality. Neurology 1967, 57(10 (Suppl. 3)):S22-S26.
2. Deuschl G., Raethjen J., Baron R., Lindemann M., Wilms H., Krack P. The pathophysiology of parkinsonian tremor: a review. J Neurology 2000, 247(Suppl. 5). V/33-48.
3. Adams R.D., Victor M. Tremors, myoclonus, spasms and tics. Principles of neurology 1995, McGraw-Hill, New York, p. 69-79.
4. Koster B., Lauk M., Timmer J., Lucking C.H. Side to side correlation of pathological tremors. Electroencephalography and Clinical Neurophysiology 1997, 103:211-220.
5. Salamone J.D., Mayorga A.J., Trevitt J.T., Cousins M.S., Conlan A., Nawab A. Tremulous jaw movements in rats: a model of parkinsonian tremor. Progress in Neurobiology 1998, 56:591-611.
6. Morrison S., Kerr G., Silburn P. Bilateral tremor relations in Parkinson's disease: effects of mechanical coupling and medication. Parkinsonism & Related Disorders 2008, 14:298-308.
7. Mansur P.H., Cury L.K., Andrade A.O., Pereira A.A., Miotto G.A., Soares A.B., et al. A review of techniques for tremor recording and quantification. Critical Reviews in Biomedical Engineering 2007, 35(5):343-362.
8. Wilms H., Sievers J., Deuschl G. Animal models of tremor. Movement Disorders 1999, 14:557-571.
9. Deuschl G., Raethjen J., Lindemann M., Krack P. The pathophysiology of tremor. A review. Muscle Nerve 2001, 24(6):716-735.
10. Bergman H., Deuschl G. Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back. Movement Disorders 2002, 17(Suppl. 3):S28-S40.
11. Sung Y.H., Chung S.J., Kim S.R., Lee M.C. Factors predicting response to dopaminergic treatments for resting tremor of Parkinson's disease. Movement Disorders 2008, 23:137-140.
12. Muthuraman M., Govindan R.B., Deuschl G., Heute U., Raethjen J. Differentiating phase shift and delay in narrow band coherent signals. Clinical Neurophysiology 2008, 119:1062-1070.
13. Salamone J.D., Correa M., Carlson B., Wisniecki A., Mayorga A., Nisenbaum E., et al. Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents. Implications for cholinergic involvement in parkinsonism. Life Sciences 2001, 68:2579-2584.
14. Salamone J.D., Carlson B.B., Rios C., Lentini E., Correa M., Wisniecki A., et al. Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243. Behavioural Brain Research 2005, 156:173-179.
15. Salamone J.D., Ishiwari K., Betz A.J., Farrar A.M., Mingote S.M., Font L., et al. Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism. Parkinsonism & Related Disorders 2008, 14:S130-S134.
16. Collins-Praino L.E., Paul N.E., Rychalsky K.L., Hinman J.R., Chrobak J.J., Senatus P.B., et al. Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor. Frontiers in Systems Neuroscience 2011, 5:49.
17. Cenci M.A., Whishaw I.Q., Schallert T. Animal models of neurological deficits: how relevant is the rat. Nature Reviews Neuroscience 2002, 3:574-579.
18. Jicha G., Salamone J.D. Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletions: possible model of parkinsonian symptoms. Journal of Neuroscience 1991, 11:3822-3829.
19. Baskin P., Salamone J.D. Vacuous jaw movements in rats induced by acute reserpine administration: interactions with different doses of apomorphine. Pharmacology Biochemistry and Behavior 1993, 46:793-797.
20. Steinpreis R.E., Salamone J.D. Effects of acute haloperidol and reserpine administration on vacuous jaw movements in three different age groups of rats. Pharmacology Biochemistry and Behavior 1993, 46:405-409.
21. Finn M., Jassen A., Baskin P., Salamone J.D. Tremulous characteristic of vacuous jaw movements induced by pilocarpine and ventrolateral striatal dopamine depletions. Pharmacology Biochemistry and Behavior 1997, 57:243-249.
22. Rodriguez Diaz M., Abdala P., Barroso-Chinea P., Obeso J., Gonzalez-Hernandez T. Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease. Behavioural Brain Research 2001, 122:79-92.
23. Salamone J.D., Betz A.J., Ishiwari K., Felsted J., Madson L., Mirante B., et al. Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism. Frontiers in Bioscience 2008, 13:3594-3605.
24. Steinpreis R.E., Baskin P., Salamone J.D. Vacuous jaw movements induced by sub-chronic administration of haloperidol: interactions with scopolamine. Psychopharmacology 1993, 111:99-105.
25. Trevitt J.T., Atherton A., Aberman J., Salamone J.D. Effects of subchronic administration of clozapine, thioridazine and haloperidol on tests related to extrapyramidal motor function in the rat. Psychopharmacology 1998, 137:61-66.
26. Wisniecki A., Correa M., Arizzi M.N., Ishiwari K., Salamone J.D. Motor effects of GABA (A) antagonism in globus pallidus: studies of locomotion and tremulous jaw movements in rats. Psychopharmacology 2003, 170(2):140-149.
27. Ishiwari K., Betz A., Weber S., Felsted J., Salamone J.D. Validation of the tremulous jaw movement model for assessment of the motor effects of typical and atypical antipychotics: effects of pimozide (Orap) in rats. Pharmacology Biochemistry and Behavior 2005, 80:351-362.
28. Betz A.J., McLaughlin P.J., Burgos M., Weber S.M., Salamone J.D. The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology 2007, 194:347-359.
29. Salamone J.D., Lalies M.D., Channell S.L., Iversen S.D. Behavioural and pharmacological characterization of the mouth movements induced by muscarinic agonists in the rat. Psychopharmacology 1986, 88:467-471.
30. Salamone J.D., Johnson C.J., McCullough L.D., Steinpreis R.E. Lateral striatal cholinergic mechanisms involved in oral motor activities in the rat. Psychopharmacology 1990, 102:529-534.
31. Mayorga A.J., Carriero D.L., Cousins M.S., Gianutsos G., Salamone J.D. Tremulous jaw movements produced by acute tacrine administration: possible relation to parkinsonian side effects. Pharmacology Biochemistry and Behavior 1997, 56:273-279.
32. Cousins M.S., Finn M., Trevitt J., Carriero D.L., Conlan A., Salamone J.D. The role of ventrolateral striatal acetylcholine in the production of tacrine-induced jaw movements. Pharmacology Biochemistry and Behavior 1999, 62:439-447.
33. Mayorga A.J., Gianutsos G., Salamone J.D. Effects of striatal injections of 8-bromo-cyclic-AMP on pilocarpine-induced tremulous jaw movements in rats. Brain Research 1999, 829:180-184.
34. Mayorga A.J., Cousins M.S., Trevitt J.T., Conlan A., Gianutsos G., Salamone J.D. Characterization of the muscarinic receptor subtype mediating pilocarpine-induced tremulous jaw movements in rats. European Journal of Pharmacology 1999, 364:7-11.
35. Simola N., Fenu S., Baraldi P.G., Tabrizi M.A., Morelli M. Blockade of adenosine A2A receptors anatagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Experimental Neurology 2004, 189:182-188.
36. 1 antagonist DPCPX: Possible relevance for drug-induced parkinsonism. Pharmacology Biochemistry and Behavior 2010, 94:561-569.
37. Collins L.E., Paul N.E., Abbas S.F., Leser C.E., Galtieri D.J., Chrobak J.J., et al. Oral tremor induced by galantamine in rats: a model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease. Pharmacology Biochemistry and Behavior 2011, 99(3):414-422.
38. Cousins M.S., Atherton A., Salamone J.D. Behavioral and electromyographic characterization of the local frequency of tacrine-induced tremulous jaw movements. Physiology and Behavior 1998, 64:153-158.
39. Miwa H., Koh J., Kajimoto Y., Kondo T. Effects of T-type calcium channel blockers on a parkinsonian tremor model in rats. Pharmacology Biochemistry and Behavior 2011, 97:656-659.
40. Cousins M.S., Carriero D.L., Salamone J.D. Tremulous jaw movements induced by the acetylcholinesterase inhibitor tacrine: effects of antiparkinsonian drugs. European Journal of Pharmacology 1997, 322:137-145.
41. Correa M., Wisniecki A., Betz A., Dobson D.R., O'Neill M.F., O'Neill M.J., et al. The adenosine A2A antagonist KF 17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behavioural Brain Research 2004, 148:47-54.
42. 2A antagonist KW-6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide. Neuroscience 2009, 163:97-108.
43. Tronci E., Simola N., Borsini F., Schintu N., Frau L., Carminati P., et al. Characterization of the antiparkinsonian effects of the new adenosine A2a receptor antagonist ST1535: acute and subchronic studies in rats. European Journal of Pharmacology 2007, 566:94-102.
44. Pinna A., Schintu N., Simola N., Volpini R., Pontis S., Cristalli G., et al. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug. Neuropharmacology 2010, 58(3):613-623.
45. Kelley A.E., Bakshi V.P., Delfs J.M., Lang C.G. Cholinergic stimulation of the ventrolateral striatum elicits mouth movements in rats: pharmacological and regional specificity. Psychopharmacology 1989, 99:542-549.
46. Kikuchi de Beltran K., Koshikawa N., Saigusa T., Watanabe K., Koshida Y., Kobayashi M. Cholinergic/dopaminergic interaction in the rat striatum assessed from drug-induced repetitive oral movements. European Journal of Pharmacology 1992, 214:181-189.
47. Finn M., Mayorga A.J., Conlan A., Salamone J.D. Involvement of pallidal and nigral GABA mechanisms in the generation of tremulous jaw movements in rats. Neuroscience 1997, 80:532-544.
48. Gerfen C.R., Keefe K.A., Gauda E.B. D1 and D2 dopamine receptor function in the striatum: co-activation of D1- and D2-dopamine receptors on separate populations of neurons in potentiated immediate early gene response in D1-containing neurons. Journal of Neuroscience 1995, 15:8167-8176.
49. Grimm J.W., See R.E. Chronic haloperidol-induced alterations in pallidal GABA and striatal D(1)-mediated dopamine turn-over as measured by dual probe microdialysis in rats. Neuroscience 2000, 100:507-514.
50. LeMoine C., Bloch B. D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of dorsal and ventral striatum. Journal of Comparative Neurology 1995, 355:418-426.
51. DeLong M.R. Primate model of movement disorders of basal ganglia origin. Trends in Neurosciences 1990, 13:281-285.
52. Young A., Penney J. Biochemical and functional organization of the basal ganglia. Parkinson's disease and movement disorders 1993, 1-12. Williams & Wilkins, Baltimore. J. Jankovic, E. Tolosa (Eds.).
53. O'Connor W.T., Osborne P.G., Ungerstedt U. Tolerance to catalepsy following chronic haloperidol is not associated with changes in GABA release in the globus pallidus. Brain Research 1998, 787:299-303.
54. Drew K.L., O'Connor W.T., Kehr J., Ungerstedt U. Regional specific effects of clozapine and haloperidol on GABA and dopamine release in rat basal ganglia. European Journal of Pharmacology 1990, 187(3):385-397.
55. Chapman M.A., See R.E. Differential effects of unique profile antipsychotic drugs on extracellular amino acids in the ventral pallidum and globus pallidus of rats. Journal of Pharmacology and Experimental Therapeutics 1996, 277:1586-1594.
56. See R.E., Berglind W.J., Krentz L., Meshul C.K. Convergent evidence from microdialysis and presynaptic immunolabeling for the regulation of gamma-aminobutyric acid release in the globus pallidus following acute clozapine or haloperidol administration in rats. Journal of Neurochemistry 2002, 82:172-180.
57. Rupniak N.M.J., Jenner P., Marsden C.D. Cholinergic modulation of perioral behavior induced by chronic neuroleptic administration to rats. Psychopharmacology 1983, 79:226-230.
58. Rupniak N.M.J., Jenner P., Marsden C.D. Pharmacological characterization of spontaneous or drug-induced purposeless chewing movements in rats. Psychopharmacology 1985, 85:71-79.
59. Stewart B.R., Rose S., Jenner P., Marsden C.D. Pilocarpine-induced purposeless chewing behaviour in rats is dependent on intact central stores of 5-HT. European Journal of Pharmacology 1987, 142:173-176.
60. Stewart B.R., Jenner P., Marsden C.D. The pharmacological characterization of pilocarpine-induced chewing in the rat. Psychopharmacology 1988, 97:228-234.
61. Baskin P., Gianutsos G., Salamone J.D. Repeated scopolamine injections sensitize rats to pilocarpine-induced vacuous jaw movements and enhance striatal muscarinic receptor binding. Pharmacology Biochemistry and Behavior 1994, 49:437-442.
62. Ishiwari K., Mingote S., Correa M., Trevitt J.T., Carlson B.B., Salamone J.D. The GABA uptake inhibitor beta-alanine reduces pilocarpine-induced tremor and increases extracellular GABA in substantia nigra pars reticulata as measured by microdialysis. Journal of Neuroscience Methods 2004, 140:39-46.
63. Trevitt J.T., Carlson B.B., Correa M., Keene A., Morales M., Salamone J.D. Interactions between dopamine D1 receptors and GABA mechanisms in substantia nigra pars reticulata: Neurochemical and behavioral studies. Psychopharmacology 2002, 159:229-237.
64. Phillips J.B., Cox B.M. Release of endogenous glutamate and gamma-aminobutyric acid from rat striatal tissue slices measured by an improved method of high-performance liquid chromatography with electrochemical detection. Journal of Neuroscience Methods 1997, 75:207-214.
65. Keppel G. Design and analysis: a researcher's handbook 1991, Prentice Hall.
66. Salamone J.D., Correa M., Farrar A.M., Nunes E.J., Collins L.E. The role of dopamine/adenosine interactions in the brain circuitry regulating effort-related decision making: Insights into pathological aspects of motivation. Future Neurology 2010, 5(3):377-392.
67. Dragunow M., Robertson G.S., Faull R.L.M., Robertson H.A., Jansen K. D2 dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons. Neuroscience 1990, 37:287-294.
68. Nguyen T.V., Kosofsky B.E., Birnbaum R., Cohen B.M., Hyman S.E. Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:4270-4274.
69. Merchant K.M., Dorsa D.M. Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:3447-3451.
70. MacGibbon G.A., Lawlor P.A., Bravo R., Dragunow M. Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Molecular Brain Research 1994, 23:21-32.
71. Semba J., Sakai M., Miyoshi R., Mataga N., Fukamauchi F., Kito S. Differential expression of c-fos mRNA in rat pre-frontal cortex, striatum, N accumbens and lateral septum after typical and atypical antipsychotics: an in situ hybridization study. Neurochemistry International 1996, 29:435-442.
72. Semba J., Sakai M.W., Suhara T., Akanuma N. Differential effects of acute and chronic treatment with typical and atypical neuroleptics on c-fos mRNA expression in rat forebrain regions using non-radioactive in situ hybridization. Neurochemistry International 1999, 34:269-277.
73. Merchant K.M., Dobie D.J., Filloux F.M., Totzke M., Aravagiri M., Dorsa D.M. Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions. Journal of Pharmacology and Experimental Therapeutics 1994, 271:460-471.
74. Coppens H.J., Sebens J.B., Korf J. Catalepsy, Fos protein, and dopamine receptor occupancy after long-term haloperidol treatment. Pharmacology Biochemistry and Behavior 1995, 51:175-182.
75. Sebens J.B., Koch T., Ter Horst G.J., Korf J. Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment. European Journal of Pharmacology 1995, 273:175-182.
76. Segovia K.N., Correa M., Lennington J., Connover J., Salamone J.D. Changes in nucleus accumbens and neostriatal c-Fos and DARPP-32 immunoreactivity during different stages of food-reinforced instrumental training. European Journal of Neuroscience 2012, 35:1354-1367.